Table 1.
Demographic features and study variables of the cohort (n =162)
| Variable | Frequency (%) |
|---|---|
| Sex | |
| Male | 90 (56 %) |
| Female | 72 (44 %) |
| Race | |
| White | 146 (90 %) |
| Age ≤3 years at cancer diagnosis | 57 (35 %) |
| History of leukemia relapse | 8 (5 %) |
| CNS leukemia at diagnosisa | 39 (24 %) |
| CNS radiation | 23 (14 %) |
| Stem cell transplantation | 0 (0 %) |
| Intravenous methotrexate dose | 25 (15 %) |
| ≥ 5 g/m2 | |
| Number of intrathecal chemotherapy dosesb | |
| Median (range) | 9 (9-23) |
| 9-12 | 100 (61.7 %) |
| ≥13 | 62 (38.3 %) |
| Body mass index at diagnosis | |
| Overweight | 39 (24 %) |
| Obese | 44 (27 %) |
| Hypertension | |
| Pre | 15 (9 %) |
| Definite | 6 (4 %) |
| Median age at cancer diagnosis (range) | 3.9 years (0.4-18.6) |
| Median age at study enrollment (range | 15.7 years (6.9-29.0) |
| Median time from cancer diagnosis (range) | 10.2 years (range 5-22.7) |
| Time from last treatment | |
| Median (range) | 7.4 years (1.9-20.3) |
| 25th quartile | 4.0 years |
| 75th quartile | 10.6 years |
| Median hemoglobin level (range) | 13.9 g/dL (11.4-17.2) |
a
Both CNS2 and CNS3
b
All participants received triple intrathecal therapy with cytarabine, methotrexate, and hydrocortisone